Sepideh Elyasi

1.8k total citations
82 papers, 1.3k citations indexed

About

Sepideh Elyasi is a scholar working on Infectious Diseases, Oncology and Molecular Biology. According to data from OpenAlex, Sepideh Elyasi has authored 82 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 17 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Sepideh Elyasi's work include Silymarin and Mushroom Poisoning (11 papers), Cancer Treatment and Pharmacology (10 papers) and COVID-19 Clinical Research Studies (8 papers). Sepideh Elyasi is often cited by papers focused on Silymarin and Mushroom Poisoning (11 papers), Cancer Treatment and Pharmacology (10 papers) and COVID-19 Clinical Research Studies (8 papers). Sepideh Elyasi collaborates with scholars based in Iran, United Kingdom and United States. Sepideh Elyasi's co-authors include Hossein Khalili, Simin Dashti‐Khavidaki, Amirhooshang Mohammadpour, Gholamreza Karimi, Sare Hosseini, Amir Hooshang Mohammadpour, Fatemeh Jafari, Mahmoud Reza Jaafari, Zhila Taherzadeh and Seyed Mahdi Rezayat and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Oncology and Food and Chemical Toxicology.

In The Last Decade

Sepideh Elyasi

72 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sepideh Elyasi Iran 17 384 318 226 179 176 82 1.3k
Khalid Al‐Rasadi Oman 31 171 0.4× 324 1.0× 580 2.6× 134 0.7× 146 0.8× 114 3.0k
Joseph F. Standing United Kingdom 25 750 2.0× 279 0.9× 141 0.6× 198 1.1× 173 1.0× 126 2.1k
Daniel P. Healy United States 23 873 2.3× 361 1.1× 169 0.7× 219 1.2× 98 0.6× 62 1.7k
Edith Lackner Austria 19 442 1.2× 167 0.5× 142 0.6× 167 0.9× 94 0.5× 46 1.4k
Zheng Jiao China 27 366 1.0× 293 0.9× 239 1.1× 55 0.3× 75 0.4× 109 1.9k
Yasuhiro Tsuji Japan 21 535 1.4× 546 1.7× 254 1.1× 111 0.6× 108 0.6× 100 1.5k
Olivier Petitjean France 22 667 1.7× 246 0.8× 225 1.0× 330 1.8× 213 1.2× 89 1.6k
Lee B. Barradell 18 323 0.8× 181 0.6× 165 0.7× 155 0.9× 119 0.7× 24 1.3k
Leo Stolk Netherlands 23 623 1.6× 216 0.7× 468 2.1× 47 0.3× 128 0.7× 68 2.4k
Jaya Natarajan United States 19 567 1.5× 108 0.3× 169 0.7× 242 1.4× 88 0.5× 44 1.4k

Countries citing papers authored by Sepideh Elyasi

Since Specialization
Citations

This map shows the geographic impact of Sepideh Elyasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sepideh Elyasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sepideh Elyasi more than expected).

Fields of papers citing papers by Sepideh Elyasi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sepideh Elyasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sepideh Elyasi. The network helps show where Sepideh Elyasi may publish in the future.

Co-authorship network of co-authors of Sepideh Elyasi

This figure shows the co-authorship network connecting the top 25 collaborators of Sepideh Elyasi. A scholar is included among the top collaborators of Sepideh Elyasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sepideh Elyasi. Sepideh Elyasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Daryani, Nasser Ebrahimi, Elahe Tajeddin, Mahmoud Reza Jaafari, et al.. (2025). Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind clinical trial. Naunyn-Schmiedeberg s Archives of Pharmacology. 399(2). 2243–2255.
2.
Abedi, Farshad, et al.. (2025). Renal manifestations of brucellosis: a case report. Journal of Medical Case Reports. 19(1). 108–108.
3.
Elyasi, Sepideh, et al.. (2024). “The protective effect of nano curcumin supplementation on doxorubicin induced cardiotoxicity in breast cancer patients; a randomized, double-blind clinical trial”. Journal of Oncology Pharmacy Practice. 31(7). 1076–1085. 2 indexed citations
4.
Karimi, Gholamreza, et al.. (2024). Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer. Journal of Oncology Pharmacy Practice. 31(6). 965–976. 1 indexed citations
5.
Elyasi, Sepideh, et al.. (2023). Preventive and therapeutic use of herbal compounds against doxorubicin induced hepatotoxicity: a comprehensive review. Naunyn-Schmiedeberg s Archives of Pharmacology. 396(8). 1595–1617. 14 indexed citations
6.
Tajik, A. Jamil, Shekoufeh Nikfar, Sepideh Elyasi, Omid Rajabi, & Mehdi Varmaghani. (2023). Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran. Child and Adolescent Psychiatry and Mental Health. 17(1). 115–115. 3 indexed citations
7.
Jafari, Fatemeh, et al.. (2023). Prevention of colistin-induced neurotoxicity: a narrative review of preclinical data. Naunyn-Schmiedeberg s Archives of Pharmacology. 397(6). 3709–3727. 4 indexed citations
8.
Elyasi, Sepideh, et al.. (2022). Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical. DARU Journal of Pharmaceutical Sciences. 30(1). 117–125. 6 indexed citations
9.
Karbasforooshan, Hedyieh, et al.. (2022). Silymarin as a preventive or therapeutic measure for chemotherapy and radiotherapy-induced adverse reactions: a comprehensive review of preclinical and clinical data. European Journal of Clinical Pharmacology. 79(1). 15–38. 14 indexed citations
10.
Varmaghani, Mehdi, et al.. (2022). Availability and affordability of anticancer medicines in Iran based on WHO/HAI standard survey methods. Supportive Care in Cancer. 31(1). 89–89. 3 indexed citations
11.
Javadinia, Seyed Alireza, et al.. (2021). Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial. Journal of Oncology Pharmacy Practice. 28(4). 827–835. 30 indexed citations
12.
Elyasi, Sepideh, et al.. (2021). The Role of Antioxidants in the Management of Obsessive‐Compulsive Disorder. Oxidative Medicine and Cellular Longevity. 2021(1). 2 indexed citations
13.
14.
Abedi, Farshad, Mahin Ramezani, Reza Dehghan, et al.. (2021). Ethnobotany, Phytochemistry and Pharmacological Features of Centella asiatica: A Comprehensive Review. Advances in experimental medicine and biology. 1308. 451–499. 27 indexed citations
15.
Elyasi, Sepideh, et al.. (2020). Chemotherapy Administration Safety Standards for Preventing Medication Error in Patients with Hodgkin and Non-Hodgkin Lymphoma. SHILAP Revista de lepidopterología. 11(2). 203–208. 1 indexed citations
16.
Elyasi, Sepideh, et al.. (2020). Curcumin as a preventive or therapeutic measure for chemotherapy and radiotherapy induced adverse reaction: A comprehensive review. Food and Chemical Toxicology. 145. 111699–111699. 43 indexed citations
17.
18.
19.
Karimzadeh, Iman, et al.. (2013). Carnitine and Sepsis: A Review of an Old Clinical Dilemma. Journal of Pharmacy & Pharmaceutical Sciences. 16(3). 414–414. 22 indexed citations
20.
Elyasi, Sepideh, et al.. (2012). Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. European Journal of Clinical Pharmacology. 69(4). 747–754. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Khalid Al‐Rasadi Breakdown of academic impact, for papers by Joseph F. Standing Breakdown of academic impact, for papers by Daniel P. Healy Breakdown of academic impact, for papers by Edith Lackner Breakdown of academic impact, for papers by Zheng Jiao Breakdown of academic impact, for papers by Yasuhiro Tsuji Breakdown of academic impact, for papers by Olivier Petitjean Breakdown of academic impact, for papers by Lee B. Barradell Breakdown of academic impact, for papers by Leo Stolk Breakdown of academic impact, for papers by Jaya Natarajan
Rankless by CCL
2026